Methods and compositions for treating hemophilia B

Patent metadata

Field	Value
Publication number	US-9629930-B2
Application number	US-201514878703-A
Country	US
Kind code	B2
Filing date	Oct 8, 2015
Priority date	Oct 12, 2010
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

Disclosed herein are methods and compositions for insertion of Factor IX (FIX) sequences into the genome of a cell for treating hemophilia B.

First claim

What is claimed is:

1. A method for treating hemophilia B in a subject, the method comprising integrating a sequence encoding a functional Factor IX (FIX) protein or fragment thereof into the genome of a cell using at least one zinc finger nuclease, wherein the zinc finger nuclease comprises an engineered zinc finger protein DNA-binding domain that binds to a target site in an endogenous Factor IX (FIX) gene, wherein the DNA-binding domain comprises four or five zinc finger recognition regions ordered F1 to F4 or F1 to F5 from N-terminus to C-terminus, and wherein
(i) when the DNA-binding domain comprises five zinc finger recognition regions, F1 to F5 comprise the following amino acid sequences:

(SEQ ID NO: 4)

F1:
QSGDLTR

(SEQ ID NO: 5)

F2:
RSDVLSE

(SEQ ID NO: 6)

F3:
DRSNRIK

(SEQ ID NO: 7)

F4:
RSDNLSE

(SEQ ID NO: 8)

F5:
QNATRIN,

wherein the DNA-binding domain binds to the target site shown in SEQ ID NO:3; and
(ii) when the DNA-binding domain comprises four zinc finger recognition regions, F1 to F4 comprise the following amino acid sequences:

(SEQ ID NO: 10)

F1:
RSDSLSV

(SEQ ID NO: 11)

F2:
TSGHLSR

(SEQ ID NO: 12)

F3:
RSDHLSQ

(SEQ ID NO: 13)

F4:
HASTRHC,

wherein the DNA-binding domain binds to the target site shown in SEQ ID NO:9.

2. The method of claim 1 , wherein the sequence is integrated into an endogenous gene FIX gene.

3. The method of claim 1 , wherein the sequence is delivered to the cell using a vector selected from the group consisting of a viral vector, a non-viral vector and combinations thereof.

4. The method of claim 1 , wherein the at least one zinc finger nuclease is delivered to the cell using a vector selected from the group consisting of a viral vector, a non-viral vector and combinations thereof.

5. The method of claim 1 , wherein the cell is a hepatic cell and the sequence is delivered to the cell by intravenous administration into the liver of an intact animal, intraperitoneal administration, direct injection into liver parenchyma, injection into the hepatic artery, or retrograde injection through the biliary tree.

6. The method of claim 1 , further comprising the step of performing a partial hepatectomy on the subject.

7. The method of claim 1 , further comprising the step of treating the subject with at least one secondary agent.

8. The method of claim 7 , wherein the secondary agent is selected from the group consisting of gamma irradiation, UV irradiation, tritiated nucleotides, cis-platinum, etoposide, hydroxyurea, aphidicolin, prednisolone, carbon tetrachloride, adenovirus and combinations thereof.

9. The method of claim 1 , wherein the cell is an isolated cell and the method further comprises administering the isolated cell to the subject.

10. The method of claim 9 wherein the zinc finger nuclease is delivered to the cell as an RNA.

11. The method of claim 1 , wherein the subject is selected from the group consisting of an embryo, a fetus, a neonate, an infant, a juvenile or an adult.

12. The method of claim 1 , further comprising associating the sequence with a homing agent that binds specifically to a surface receptor of the cell.

13. The method of claim 12 , wherein the homing agent comprises galactose or a hybrid of an AAV coat protein and galactose.

14. The method of claim 1 , further comprising associating a polynucleotide encoding the at least one nuclease with a homing agent that binds specifically to a surface receptor of the cell.

15. The method of claim 14 , wherein the homing agent comprises galactose or a hybrid of an AAV coat protein and galactose.

Assignees

• Sangamo Biosciences Inc
• The Children'S Hospital Of Philadelphia

Inventors

• Gregory Philip D
• High Katherine A
• Holmes Michael C
• Li Hojun

Classifications

• C12Y304/21022

  Coagulation factor IXa (3.4.21.22) · CPC title

• A61K48/005 Primary

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title

• C12N9/644

  Coagulation factor IXa (3.4.21.22) · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12Y304/21002

  Chymotrypsin C (3.4.21.2) · CPC title